Celgene's 4th quarter 2017 sales and profit beat estimates

http://alph.st/ba1df6ff Higher sales of Revlimid and Otezla help Celgene to report better than expected sales figure. Will the two (Impact and Juno) multi-billion dollar acquisitions help the struggling Celgene in 2018 and beyond?

 

but, but, but there's no way you can sell that much Otezla without having a biologics pro on-board

signed, liddle fella

 

struggling Celgene. Yea, continued double digit growth. Problem was, not big enough double digit growth! Not sure if “struggling is the right term. Performance in q3 was under expectations . Maybe time for a “come back”! Glad I’m here !

 

is the stock ever gonna break $100 again?